Journal of the American Academy of Dermatology · 2016 · 162 citations · 23 references
MedicineDermatologyOncologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyBasal Cell CarcinomaHedgehog SignalingMalignant NeoplasmsSquamous Cell CarcinomaAdvanced Basal Cell Carcinoma TherapyDermatologic Adverse EventsDouble-blind TrialsHedgehog Pathway InhibitorsMetastatic Basal Cell CarcinomaPhase Ii InvestigationShrinkageTumor Shrinkage Assessment
BACKGROUND: The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study. OBJECTIVE: This report provides long-term follow-up data collected up to 12 months after the last patient was randomized. METHODS: In this multicenter, randomized, double-blind phase II study, patients were randomized 1:2 to sonidegib 200 or 800 mg. The primary end point was objective response rate assessed by central review. RESULTS: Objective response rates in the 200- and 800-mg arms were 57.6% and 43.8% in locally advanced BCC and 7.7% and 17.4% in metastatic BCC, respectively. Among the 94 patients with locally advanced BCC who responded, only 18 progressed or died and more than 50% had responses lasting longer than 6 months. In addition, 4 of 5 responders with metastatic BCC maintained an objective response. Grade 3/4 adverse events and those leading to discontinuation were less frequent with sonidegib 200 versus 800 mg (38.0% vs 59.3%; 27.8% vs 37.3%, respectively). LIMITATIONS: No placebo or comparator arms were used because sonidegib demonstrated efficacy in advanced BCC in a phase I study, and the hedgehog pathway inhibitor vismodegib was not yet approved. CONCLUSION: With longer follow-up, sonidegib demonstrated sustained tumor responses in patients with advanced BCC.
23
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
The National Comprehensive Cancer Network
William T. McGivney · Cancer · 1998 · 16.9K citations
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro et al. · New England Journal of Medicine · 2012 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17